Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology-Tyler
mi
from
Tyler, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of Virginia
mi
from
Charlottesville, VA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
mi
from
Salem, VA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
mi
from
Salem, VA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Virginia Mason Medical Center
mi
from
Seattle, WA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Cancer Care Northwest
mi
from
Spokane, WA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Cancer TEAM Bellin Health
mi
from
Green Bay, WI
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Cancer TEAM Bellin Health
mi
from
Green Bay, WI
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Arizona Oncology Associates, PC- NAHOA
mi
from
Flagstaff, AZ
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Arizona Oncology Associates, PC- NAHOA
mi
from
Flagstaff, AZ
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pasadena, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pasadena, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of California at San Francisco
mi
from
San Francisco, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of Miami School of Medicine
mi
from
Miami, FL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of Miami School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Oncology Specialists
mi
from
Niles, IL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Oncology Specialists
mi
from
Niles, IL
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Illinois Cancer Care
mi
from
Peoria, IL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
The Mayo Clinic
mi
from
Rochester, MN
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Coborn Cancer Center
mi
from
St. Cloud, MN
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Coborn Cancer Center
mi
from
St. Cloud, MN
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Washington University, St. Louis
mi
from
St. Louis, MO
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Washington University, St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Cooper University Hospital
mi
from
Voorhees, NJ
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Cooper University Hospital
mi
from
Voorhees, NJ
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Beth Israel Medical Center
mi
from
New York City, NY
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Beth Israel Medical Center
mi
from
New York City, NY
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Cornell university
mi
from
New York city, NY
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Cornell university
mi
from
New York city, NY
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
SUNY Upstate Medical University
mi
from
Syracuse, NY
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Carolinas Hematology-Oncology Associates
mi
from
Charlotte, NC
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Carolinas Hematology-Oncology Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Cancer Centers of the Carolinas
mi
from
Easley, SC
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Cancer Centers of the Carolinas
mi
from
Easley, SC
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Institut Jules Bordet
mi
from
Bruxelles,
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Institut Jules Bordet
mi
from
Bruxelles,
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Alabaster, AL
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Alabaster, AL
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Encinitas, CA
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Encinitas, CA
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Gilroy, CA
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Gilroy, CA
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Long Beach, CA
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Davie, FL
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Davie, FL
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Orlando, FL
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Rochester, MN
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
St. Louis, MO
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Berkeley Heights, NJ
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Berkeley Heights, NJ
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
New York, NY
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Fargo, ND
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Columbus, OH
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Nashville, TN
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
El Paso, TX
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Houston, TX
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Clinical Research Facility
mi
from
Lacey, WA
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Clinical Research Facility
mi
from
Lacey, WA
Click here to add this to my saved trials
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated:  9/17/2015
Research Site
mi
from
Waratah,
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor
Status: Enrolling
Updated: 9/17/2015
Research Site
mi
from
Waratah,
Click here to add this to my saved trials
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node
Status: Enrolling
Updated:  9/18/2015
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node
Status: Enrolling
Updated: 9/18/2015
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials